Welcome to our dedicated page for Theratechnologies SEC filings (Ticker: THTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Theratechnologies Inc. filings document foreign-issuer current reports, shareholder materials and corporate-status disclosures for a commercial-stage biopharmaceutical company. The record includes Form 6-K reports furnished with press releases, a material change report, special meeting materials, a management proxy circular, proxy forms, voting instructions and a letter of transmittal.
The filings also document the company’s common shares, capital-structure matters, governance and shareholder voting processes, product and business updates, and a Form 25 notification of removal from Nasdaq listing and registration under Section 12(b) of the Exchange Act following the completed acquisition transaction.
Summer Road LLC filed a Schedule 13G reporting beneficial ownership of 2,683,591 Common Shares of Theratechnologies Inc. (CUSIP 88338H704), representing 5.84% of the 45,980,019 shares outstanding cited from the issuer's Form 20-F. The Reporting Person is a Delaware family office that holds these shares through investment management agreements with two Family Clients, identified as Cap 1 LLC and East River Partners Ltd. The filing states the shares are held passively and were not acquired to influence control of the issuer.
Theratechnologies Inc. submitted a Form 25 notice (Commission File No. 001-35203) indicating removal of its class of securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing states the Exchange has complied with the rules for striking the securities and that the issuer has complied with voluntary withdrawal requirements. Contact and address details for the issuer are provided.
Theratechnologies Inc. furnished a Form 6-K as a foreign private issuer for August 2025. The filing mainly forwards materials for a special meeting of shareholders, including a notice of meeting and a management proxy circular, both dated August 12, 2025.
The report also includes a form of proxy, a voting instruction form, and a letter of transmittal as exhibits, indicating shareholders are being asked to vote on matters described in the proxy materials. The document is signed on behalf of Theratechnologies by its General Counsel and Corporate Secretary, Jocelyn Lafond, dated August 18, 2025.
Schedule 13G/A (Amendment 3) filed by Morgan Stanley discloses that its ownership in Theratechnologies Inc. (THTX) has fallen below the 5 % reporting threshold. As of 30 Jun 2025, the bank beneficially owns 858,614 common shares (CUSIP 88338H704), equal to 1.9 % of the outstanding class.
- Sole voting power: 0 shares
- Shared voting power: 852,939 shares
- Sole dispositive power: 0 shares
- Shared dispositive power: 858,614 shares
The filer is classified as a parent holding company/control person (HC, CO). Morgan Stanley certifies the shares are held in the ordinary course of business and not with intent to influence control. The amendment serves to notify investors that Morgan Stanley is no longer a 5 %+ beneficial owner of THTX.